February 28, 2018 07:35 AM EST

Dialing down the toxic effects of radiation on cancer patients, Galera gets breakthrough status on Phase IIb data

Brittany Meiling

A biotechnology company near Philadelphia — armed with data from a Phase IIb trial — just got breakthrough status from the FDA for a drug that might …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dialing down the toxic effects of radiation on cancer patients, Galera gets breakthrough status on Phase IIb data

Brittany Meiling

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Di­al­ing down the tox­ic ef­fects of ra­di­a­tion on can­cer pa­tients, Galera gets break­through sta­tus on Phase IIb da­ta

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Dialing down the toxic effects of radiation on cancer patients, Galera gets breakthrough status on Phase IIb data